Moiseyev, V. S.Põder, P.Andrejevs, N.Ruda, M. Y.Golikov, A. P.Lazebnik, L. B.Kobalava, Z. D.Lehtonen, L. A.Laine, T.Nieminen, Markku S.Lie, K. I.2021-10-012021-10-012002-09Moiseyev, V S, Põder, P, Andrejevs, N, Ruda, M Y, Golikov, A P, Lazebnik, L B, Kobalava, Z D, Lehtonen, L A, Laine, T, Nieminen, M S & Lie, K I 2002, 'Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction : A randomized, placebo-controlled, double-blind study (RUSSLAN)', European Heart Journal, vol. 23, no. 18, pp. 1422-1432. https://doi.org/10.1053/euhj.2001.31580195-668Xhttps://dspace.rsu.lv/jspui/handle/123456789/6487Aims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. Methods and Results: Levosimendan at different doses (0·1-0·4 μg . kg-1 . min-1) or placebo were administered intravenously for 6 h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0·319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2·0% vs 5·9%; P=0·033) and over 24 h (4·0% vs 8·8%; P=0·044). Mortality was lower with levosimendan compared with placebo at 14 days (11·7% vs 19·6%; hazard ratio 0·56 [95% CI 0·33-0·951; P=0·031) and the reduction was maintained at the 180-day retrospective follow-up (22·6% vs 31·4%; 0·67 [0·45-1·00], P=0·053). Conclusions: Levosimendan at doses 0·1-0·2 μg . kg-1 . min-1 did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.11173047enginfo:eu-repo/semantics/openAccessHypotensionIschaemiaLeft ventricular failureLevosimendanMortalityMyocardial infarction3.2 Clinical medicine1.1. Scientific article indexed in Web of Science and/or Scopus databaseCardiology and Cardiovascular Medicine/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1053/euhj.2001.3158http://www.scopus.com/inward/record.url?scp=0036764821&partnerID=8YFLogxKhttps://academic.oup.com/eurheartj/article/23/18/1422/490755https://academic.oup.com/eurheartj/article/23/18/1422/490755